

ESTUDIO	AÑO	PUBLICACIONES
S1007: "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer Study.	2013	Benefits of Adjuvant Chemotherapy Differ by Menopausal Status in Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Recurrence Score. <i>The Oncologist</i> , Volume 27, Issue Supplement_1, March 2022, Pages S15–S16, https://doi.org/10.1093/oncolo/oyac012
		First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder) <i>Cancer Res</i> (2021) 81 (4_Supplement): GS3-00. https://doi.org/10.1158/1538-7445.SABCS20-GS3-00
S1316: Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction.	2024	A Pragmatic Trial for Patients with Advanced Cancer: S1316 Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction (SWOG S1316). pub 2023 Aug 1. Erratum in: <i>Lancet Gastroenterol Hepatol.</i> 2024 Feb;9(2): e2. http://doi: 10.1016/S2468-1253(23)00459-4
	2023	Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial. Epub 2023 Aug 1. Erratum in: <i>Lancet Gastroenterol Hepatol.</i> 2024 Feb;9(2): e2. http://doi: 10.1016/S2468-1253(23)00459-4 .
S1714: A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients.	2024	Risk prediction model for Taxane-induced peripheral neuropathy (TIPN) in patients with early-stage cancer receiving taxane therapy: SWOG S1714. <i>JCO</i> 42, 12005-12005(2024). DOI: 10.1200/JCO.2024.42.16_suppl.12005

ESTUDIO	AÑO	PUBLICACIONES
A22101	2023	Alliance for Clinical Trials in Oncology (Alliance) trial A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur). <i>Res Sq [Preprint]</i> . 2023 Dec 23: rs.3.rs-3773522. doi: 10.21203/rs.3.rs-3773522/v1. Update in: <i>BMC Cancer</i> . 2024 feb 13;24(1):201. http://doi: 10.1186/s12885-024-11899-2 .